CA2185882A1 - Utilisation de dimeticone dans la therapie antibacterienne locale et/ou la prevention et la therapie des syndromes et maladies infectieuses associes a helicobacter pylori (hp) - Google Patents

Utilisation de dimeticone dans la therapie antibacterienne locale et/ou la prevention et la therapie des syndromes et maladies infectieuses associes a helicobacter pylori (hp)

Info

Publication number
CA2185882A1
CA2185882A1 CA002185882A CA2185882A CA2185882A1 CA 2185882 A1 CA2185882 A1 CA 2185882A1 CA 002185882 A CA002185882 A CA 002185882A CA 2185882 A CA2185882 A CA 2185882A CA 2185882 A1 CA2185882 A1 CA 2185882A1
Authority
CA
Canada
Prior art keywords
therapy
dimeticone
prevention
helicobacter pylori
infectious diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002185882A
Other languages
English (en)
Inventor
Alfred Schmidt
Hans-Jurgen Upmeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/EP1995/000972 external-priority patent/WO1995025525A1/fr
Publication of CA2185882A1 publication Critical patent/CA2185882A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne l'utilisation de diméthylpolysiloxane (diméticone) dans la thérapie, la prévention et le traitement antibactériens locaux des syndromes et infections associés à Helicobacter pylori.
CA002185882A 1994-03-18 1995-03-15 Utilisation de dimeticone dans la therapie antibacterienne locale et/ou la prevention et la therapie des syndromes et maladies infectieuses associes a helicobacter pylori (hp) Abandoned CA2185882A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4409357A DE4409357C2 (de) 1994-03-18 1994-03-18 Verwendung von Dimeticon zur Eradikation von Heliobacter pylori
DEP4409357.8 1994-03-18
PCT/EP1995/000972 WO1995025525A1 (fr) 1994-03-18 1995-03-15 Utilisation de dimeticone dans la therapie antibacterienne locale et/ou la prevention et la therapie des syndromes et maladies infectieuses associes a helicobacter pylori (hp)

Publications (1)

Publication Number Publication Date
CA2185882A1 true CA2185882A1 (fr) 1995-09-28

Family

ID=6513210

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002185882A Abandoned CA2185882A1 (fr) 1994-03-18 1995-03-15 Utilisation de dimeticone dans la therapie antibacterienne locale et/ou la prevention et la therapie des syndromes et maladies infectieuses associes a helicobacter pylori (hp)

Country Status (14)

Country Link
EP (1) EP0804242A1 (fr)
JP (1) JPH09510466A (fr)
CN (1) CN1244129A (fr)
AU (1) AU699199B2 (fr)
CA (1) CA2185882A1 (fr)
CZ (1) CZ300796A3 (fr)
DE (1) DE4409357C2 (fr)
FI (1) FI963682A (fr)
HU (1) HU215595B (fr)
NO (1) NO963893L (fr)
NZ (1) NZ282805A (fr)
PL (1) PL316307A1 (fr)
SK (1) SK132496A3 (fr)
WO (1) WO1995025545A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100245A (en) * 1999-09-07 2000-08-08 Mcneil-Ppc, Inc. Use of simethicone to treat ulcerative colitis
MXPA05012791A (es) * 2003-05-25 2006-02-22 Wang Yuwan Formulacion sostenida que contiene dimeticona.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3848M (fr) * 1964-05-04 1966-01-17 Robert Schapiro Associations thérapeutiques pour traitement de nombreux troubles digestifs organiques ou fonctionnels.
GB1357737A (en) * 1970-10-09 1974-06-26 Arpic Sa Sustained release pharmaceutical compositions
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
US4837029A (en) * 1987-04-06 1989-06-06 Carolina Medical Products, Inc. Low foaming, aqueously homogenizable rifampin composition
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
HU206624B (en) * 1989-01-19 1992-12-28 Steigerwald Arzneimittelwerk Process for producing pharmaceutical composition for treating illnesses of oesophagus and the gastro-intestinal system
IE903302A1 (en) * 1989-09-15 1991-04-10 Pehrom Pharmaceutical Corp Topical preparation for treatment of aphthous ulcers and¹other lesions
IN171919B (fr) * 1989-11-01 1993-02-06 Mcneil Ppc Inc
US5229137A (en) * 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn
WO1994003209A1 (fr) * 1992-07-29 1994-02-17 Merck & Co., Inc. Combinaisons dexibuprofene/antacide/simethicone

Also Published As

Publication number Publication date
HU215595B (hu) 1999-01-28
NO963893L (no) 1996-11-04
NO963893D0 (no) 1996-09-17
WO1995025545A1 (fr) 1995-09-28
DE4409357C2 (de) 1996-10-17
NZ282805A (en) 1998-02-26
AU699199B2 (en) 1998-11-26
PL316307A1 (en) 1997-01-06
FI963682A (fi) 1996-11-13
CZ300796A3 (en) 1997-09-17
CN1244129A (zh) 2000-02-09
EP0804242A1 (fr) 1997-11-05
AU2071395A (en) 1995-10-09
HU9602839D0 (en) 1996-12-30
HUT75711A (en) 1997-05-28
SK132496A3 (en) 1997-06-04
JPH09510466A (ja) 1997-10-21
FI963682A0 (fi) 1996-09-17
DE4409357A1 (de) 1995-09-21

Similar Documents

Publication Publication Date Title
Wu et al. Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis
McNabb et al. Host defense mechanisms at mucosal surfaces
JPH07500845A (ja) ヘリコバクター感染の経口治療
RU2533268C2 (ru) Композиция для профилактики или лечения нарушений желудочно-кишечного тракта, содержащая в качестве активного ингредиента s-аллил-l-цистеин
OPEKUN et al. Novel therapies for Helicobacter pylori infection
Sabah et al. Prevalence of Helicobacter pylori infection among adult patients with different gastrointestinal parasites in Tanta City district
RU2227033C2 (ru) Тауролидин и/или таурултам при лечении инфекционной язвенной болезни или инфекционного гастрита
Casswall et al. Bovine anti-Helicobacter pylori antibodies for oral immunotherapy
EP0759761A1 (fr) Utilisation de dimeticone dans la therapie antibacterienne locale et/ou la prevention et la therapie des syndromes et maladies infectieuses associes a helicobacter pylori (hp)
EP0484148A1 (fr) Procédé de préparation d'un médicament pour à la fois, le traitement et la prévention d'ulcères peptiques gastriques et de la gastrite, et des médicaments ainsi formulés
Axon Eradication of Helicobacter pylori
CA2185882A1 (fr) Utilisation de dimeticone dans la therapie antibacterienne locale et/ou la prevention et la therapie des syndromes et maladies infectieuses associes a helicobacter pylori (hp)
Liu et al. Salidroside alleviates dextran sulfate sodium-induced colitis in mice by modulating the gut microbiota
US6028062A (en) Use of dimeticone for the local antibacterial therapy and/or the prevention and therapy of helicobacter pylori (Hp) associated syndromes and infectious diseases
JPH02504389A (ja) 細菌性またはウイルス性疾患の予防および治療用医薬組成物
Fukuda Suppression of Helicobacter pylori colonization with omeprazole
KR20010110922A (ko) 헬리코박터 파이로리에 대한 개선된 ｌｇＹ 생성의유도방법 및 이에 의해 제조된 계란
CN1273193C (zh) 抗幽门螺杆菌卵黄抗体生物制剂的制备方法
Yap Prevention of infection in patients with B cell defects: focus on intravenous immunoglobulin
WO2024100615A1 (fr) Complément nutraceutique pour la prévention et le traitement d'infections des voies respiratoires
Dorvilus et al. Streptococcus milleri: a cause of pyogenic liver abscess.
Choi et al. Effect of one-or two-week triple therapy with omeprazole, amoxicillin, and clarithromycin on eradication of Helicobacter pylori infection in children
RU2187318C2 (ru) Способ лечения хронического гастрита и язвенной болезни двенадцатиперстной кишки
AU675938C (en) Oral treatment of helicobacter infection
CN114948917A (zh) 一种改善幽门螺杆菌感染模型小鼠胃黏膜病理变化的方法

Legal Events

Date Code Title Description
FZDE Discontinued